Careers Contact Us
Our Partners

Out-licensing

At Pfizer, we are constantly reassessing our portfolio of early- through late-stage assets to ensure alignment with our strategic focus. As we redefine our priorities, we have also made the decision to exit research and development efforts in certain therapeutic and disease areas.

As a result, select assets that fall outside our primary focus are made available to third parties through a variety of deal structures. Specifically, we are seeking to out license or partner on a number of programs in the following areas:

  • Cardiovascular disease
  • Dermatology
  • Gastrointestinal disease
  • Genitourinary disease
  • Inflammation
  • Pain
  • Metabolic disease
  • Neuroscience
  • Women's health

We invite companies searching for new product candidates at all phases of development to inquire about our assets.

Text SizeAAA
Print
Out-licensing

As a global company, we are constantly reassessing our portfolio of early — through late-stage assets to ensure alignment with our strategic focus. As priorities are refined we occasionally exit research and development efforts in various therapeutic and disease areas.

We invite companies searching for new product candidates at all phases of development to inquire about our assets.

Please submit your inquires to www.pfizer.com/partnering.

Submit Your Idea
Submit Your Idea

Send us your idea for consideration.


Working with Pfizer